Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia

Bone Marrow Transplantation

Volumn 35, Issue 8, 2005, Pages 767-773

  de Labarthe, A ^a   Pautas, C ^b   Thomas, X ^c   de Botton, S ^d   Bordessoule, D ^e   Tilly, H ^f   de Revel, T ^g   Bastard, C ^f   Preudhomme, C ^d   Michallet, M ^c   Fenaux, P ^h   Bastie, J N ⁱ   Socie G ^a   Cordonnier, C ^b   Dombret, Herve ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g Department of Hematology   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Prognosis

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FOLLOW UP; FRANCE; HEALTH CARE POLICY; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVING DONOR; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTICENTER STUDY; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIBLING; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; SIBLINGS; STEM CELL TRANSPLANTATION; TIME FACTORS; TISSUE DONORS; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20944451186     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704884     Document Type: Article

References (30)

1. Thomas ED, Buckner CD, Clift RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 310: 597-599.
2. Appelbaum FR, Dahlberg S, Thomas ED et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia: a prospective comparison. Ann Intern Med 1984; 101: 581-588.
3. Champlin RE, Ho WG, Gale RP et al. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985; 102: 285-291.
4. Hermans J, Suciu S, Stijnen T et al. Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Oncol 1989; 25: 545-550.
5. Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978-2986.
6. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukaemia in first remission. N Engl J Med 1998; 339: 1649-1656.
7. Keating S, de Witte T, Suciu S et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC leukaemia cooperative group and GIMEMA. Br J Haematol 1998; 102: 1344-1353.
8. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
9. Suciu S, Mandelli F, De Witte T et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232-1240.
10. Nguyen S, Leblanc T, Fenaux P et al. A white blood cell index as the main prognostic factor in t(8,21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup. Blood 2002; 99: 3517-3523.
11. Delaunay J, Vey N, Leblanc T et al. Prognosis of inv(16)/t(16,16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML intergroup. Blood 2003; 102: 462-469.
12. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for Cancer Cytogenetics. In: Mitelman F (ed). Supplement to An International System for Human Cytogenetic Nomenclature. Karger: Basel, 1991, pp 1-53.
13. Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
14. Castaigne S, Chevret S, Archimbaud E et al. Randomized comparison of double induction and timed-sequential induction to a '3 + 7' induction in adults with acute myeloid leukemia (AML). Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104: 2467-2474.
15. Archimbaud E, Thomas X, Leblond V et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-18.
16. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
17. Kantarjian HM, Keating MJ, Walters RS et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 1988; 6: 232-238.
18. Keating MJ, Kantarjian H, Smith TL et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-1080.
19. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol 1990; 33: 110-116.
20. Thalhammer F, Geissler K, Jäger U et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216-222.
21. Kern W, Schoch C, Haferlach T et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 200; 14: 226-231.
22. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
23. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
24. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
25. Döhner K, Tobis K, Ulrich R et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20: 3254-3261.
26. Preudhomme C, Sagot C, Boissel N et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association. Blood 2002; 100: 2717-2723.
27. van Waalwijk van Doorn-Khosrovani SB, Erpelinck C, Meijer J et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003; 4: 31-40.
28. Fröhling S, Schlenk RF, Stolze I et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633.
29. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845.
30. Baldus CD, Tanner SM, Ruppert AS et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 2003; 102: 1613-1618.